Observational studyRespiratory research2018
Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR).
Observational study in Respiratory research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The Clinical and Economic Impact of Biologic Agents in Asthma Management: a Systematic Review.Lung · 2026Pooled it
- Characteristics of Adult Severe Uncontrolled Asthma Patients in Primary Care and Modifications in Prescribed Inhalation Treatments.Journal of asthma and allergy · 2026Article
- Review
- Predicting Risk of Morbidities Associated with Oral Corticosteroid Prescription for Asthma.Pragmatic and observational research · 2025Article
- Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD.Advances in therapy · 2025Observational
- Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma.Journal of asthma and allergy · 2024Article
- Severe asthma trajectories in adults: findings from the NORDSTAR cohort.The European respiratory journal · 2023Observational
- Definitions of non-response and response to biological therapy for severe asthma: a systematic review.ERJ open research · 2023Review
- Healthcare expenditure and its socio-demographic and clinical predictors in Australians with poorly controlled asthma.PloS one · 2023Article
- Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden.European clinical respiratory journal · 2022Article
- Characteristics of Oral Corticosteroid Users Among Persons with Asthma on GINA Step 3 Therapy and Above: A Cross-Sectional Study in Portuguese Community Pharmacies.Journal of asthma and allergy · 2022Article
- Molecular Mechanism Underlying Effects of Wumeiwan on Steroid-Dependent Asthma: A Network Pharmacology, Molecular Docking, and Experimental Verification Study.Drug design, development and therapy · 2022Article
- Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.Respirology (Carlton, Vic.) · 2021Review
- Trends in oral corticosteroids use in severe asthma: a 14-year population-based study.Respiratory research · 2021Article
- Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Effective Asthma Management: Is It Time to Let the AIR out of SABA?Journal of clinical medicine · 2020Review
- Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments.Frontiers in medicine · 2020Review
- Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden.Allergy · 2019Article
- Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis.The World Allergy Organization journal · 2018Article
- [Use of systemic glucocorticoids for the treatment of severe asthma: Spanish Multidisciplinary Consensus].Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with severe uncontrolled asthma may receive oral corticosteroid (OCS) treatment regularly. The present study investigated the health care resource utilization and cost in regularly OCS treated Swedish asthma patients.
methodsPrimary care medical records data were linked to data from Swedish national health registries. Patients ≥18 years with a drug claim for obstructive pulmonary diseases during 2007-2009 (index date) and a prior asthma diagnosis, were classified by their OCS claims during the 12-months' post index period: regular OCS equals ≥5 mg per day; periodic OCS less than 5 mg per day; or non-OCS users. Cost of asthma- and OCS-morbidity-related health care resource utilization were calculated.
resultsA total of 15,437 asthma patients (mean age 47.8, female 62.6%), whereof 223 (1.44%) were regular OCS users, 3054 (19.7%) were periodic, and 12,160 (78.7%) were non-OCS users. Regular OCS users were older and more often females, had lower lung function, greater eosinophil count and more co-morbidities at baseline compared with the other groups. Age-adjusted annual total health care cost was three-times greater in the regular OCS group (€5615) compared with the non-OCS users (€1980) and twice as high as in the periodic OCS group (€2948). The major cost driver in the non-OCS and periodic OCS groups were primary care consultations, whereas inpatient costs were the major cost driver in the regular OCS group. The asthma related costs represented 10-12% of the total cost in all three groups.
conclusionIn this real-life asthma study in Sweden, the total yearly cost of health care resource utilization for a regular OCS user was three times greater than for a patient with no OCS use, indicating substantial economic and health care burden for asthma patients on regular oral steroid treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.